Companies in #iPSC-derived Immunotherapies
Found 1 company operating in this sector.
Fate Therapeutics is a clinical-stage biopharmaceutical company pioneering off-the-shelf NK and T-cell cancer immunotherapies derived from induced pluripotent stem cells (iPSCs). Its pipeline includes FT596 (CD19 CAR-NK), FT819 (CD19 CAR-T), and FT522 (CD19 + IL-15 CAR-NK) in hematologic malignancies and autoimmune disease.